EUVIMEDEUVIMED entdecken
Crossref

COPS5 inhibition synergizes with the antitumor effect of trastuzumab by PTEN upregulation in HER2-amplified gastric cancer

Sung-Hyun Hwang iD, Ji-Won Kim iD, Haeseong Park, Andrew J Aguirre, Kui-Jin Kim, Songji Choi, Woochan Park, Jeongmin Seo, Heejung Chae, Minsu Kang, Eun Hee Jung, Koung Jin Suh und 5 weitere

Gastric Cancer · 2025

DOI: 10.1007/s10120-025-01669-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Gastric Cancer, 2025. Verfasst von Sung-Hyun Hwang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Research Institute, Seoul National University Bundang Hospital, Seongnam, 13620, Republic of Korea. Hauptthemen laut MEDLINE: Stomach Neoplasms, Trastuzumab, Erb-b2 Receptor Tyrosine Kinases, PTEN Phosphohydrolase. Die Arbeit nennt 29 Literaturangaben. Gefördert von: NCI NIH HHS, Seoul National University Bundang Hospital Research Fund, National Research Foundation (NRF) of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: COP9 Signalosome Subunit 5 (COPS5) is a deubiquitinating enzyme that induces chemotherapy resistance. The role of COPS5 amplification in patients with gastric cancer (GC) and its therapeutic potential in HER2-amplified GC models have not been explored. METHODS: The Cancer Genome Atlas (TCGA) data were analyzed to assess the clinical relevance of COPS5 amplification in patients with GC. Functional studies using HER2-amplified GC cell lines and xenograft models evaluated the effects of COPS5 inhibition (CSN5i-3), alone or in combination with trastuzumab. RESULTS: In the curated stomach adenocarcinoma cohort (n = 294) from TCGA datasets, COPS5 amplification was significantly more frequent in patients with HER2 amplification (10.5% vs. 2.7%, P = 0.040) and was associated with worse disease-free survival after surgery (median 12.6 vs. 45.2 months, P = 0.012) and overall survival (median 21.4 months vs. not reached, P = 0.004). In HER2-amplified GC cell lines, CSN5i-3 treatment synergized with the antiproliferative effect of trastuzumab. Mechanistically, COPS5 knockout enhanced PTEN expression by ubiquitin-mediated SNAIL degradation, suppressing the AKT downstream pathway. The combination effect was dependent on PTEN expression. Accordingly, COPS5 knockout enhanced the efficacy of AKT inhibitors. In a xenograft model, the combination of CSN5i-3 and trastuzumab demonstrated synergistic antitumor effects compared to monotherapy. CONCLUSIONS: COPS5 amplification was significantly more prevalent in patients with HER2 amplification and was associated with poor outcomes after surgery. The synergistic antiproliferative effect of COPS5 inhibition and trastuzumab was attributed to increased PTEN expression via SNAIL ubiquitination, resulting in the inhibition of the AKT pathway, warranting further clinical studies in patients with HER2-positive GC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsTrastuzumabErb-b2 Receptor Tyrosine KinasesPTEN PhosphohydrolaseCOP9 Signalosome ComplexHumansAnimalsMiceFemaleXenograft Model Antitumor AssaysUp-RegulationMaleCell Line, TumorDrug SynergismGene AmplificationMiddle AgedAntineoplastic Combined Chemotherapy ProtocolsMice, NudeAdenocarcinomaCell ProliferationAntineoplastic Agents, Immunological

Stichwörter der Autor:innen

COPS5Gastric cancerPTENSNAILTrastuzumab

Substanzen

TrastuzumabErb-b2 Receptor Tyrosine KinasesPTEN PhosphohydrolaseCOP9 Signalosome ComplexAntineoplastic Agents, ImmunologicalPTEN protein, humanERBB2 protein, human

Autor:innen und Institutionen

  • Biomedical Research Institute, Seoul National University Bundang Hospital, Seongnam, 13620, Republic of Korea.
  • Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, 13620, Republic of Korea. jiwonkim@snubh…
  • Department of Genomic Medicine, Seoul National University Bundang Hospital, Seongnam, 13620, Republic of Korea. jiwonkim@snubh.org.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
  • Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, 13620, Republic of Korea.
  • Department of Genomic Medicine, Seoul National University Bundang Hospital, Seongnam, 13620, Republic of Korea.

ORCID-Profile: Sung-Hyun Hwang, Ji-Won Kim

Förderung

  • NCI NIH HHS
  • Seoul National University Bundang Hospital Research Fund
  • National Research Foundation (NRF) of Korea

Zitieren

APA

Hwang, S. H., Kim, J. W., Park, H., Aguirre, A. J., Kim, K. J., Choi, S., Park, W., Seo, J., Chae, H., Kang, M., Jung, E. H., Suh, K. J., Kim, S. H., Kim, J. W., Kim, Y. J., Kim, J. H., & Lee, K. W. (2025). COPS5 inhibition synergizes with the antitumor effect of trastuzumab by PTEN upregulation in HER2-amplified gastric cancer. Gastric Cancer. https://doi.org/10.1007/s10120-025-01669-9

Vancouver

Hwang SH, Kim JW, Park H, Aguirre AJ, Kim KJ, Choi S, et al. COPS5 inhibition synergizes with the antitumor effect of trastuzumab by PTEN upregulation in HER2-amplified gastric cancer. Gastric Cancer. 2025. doi:10.1007/s10120-025-01669-9

BibTeX
@article{Hwang2025,
  author = {Hwang, Sung-Hyun and Kim, Ji-Won and Park, Haeseong and Aguirre, Andrew J and Kim, Kui-Jin and Choi, Songji and Park, Woochan and Seo, Jeongmin and Chae, Heejung and Kang, Minsu and Jung, Eun Hee and Suh, Koung Jin and Kim, Se Hyun and Kim, Jin Won and Kim, Yu Jung and Kim, Jee Hyun and Lee, Keun-Wook},
  title = {COPS5 inhibition synergizes with the antitumor effect of trastuzumab by PTEN upregulation in HER2-amplified gastric cancer},
  journal = {Gastric Cancer},
  year = {2025},
  doi = {10.1007/s10120-025-01669-9}
}
Kostenlos starten →